Literature DB >> 29360981

From a dominant to an oligogenic model of inheritance with environmental modifiers in acute intermittent porphyria.

Hugo Lenglet1,2, Caroline Schmitt1,3,4, Thomas Grange5, Hana Manceau1,6, Narjesse Karboul1, Florian Bouchet-Crivat1, Anne-Marie Robreau1,4, Gael Nicolas1, Jerôme Lamoril7, Sylvie Simonin4, Arienne Mirmiran1, Zoubida Karim1, Enrique Casalino2,3, Jean-Charles Deybach1,3,4, Hervé Puy1,3,4,8, Katell Peoc'h1,3,6,8, Laurent Gouya1,3,4,8.   

Abstract

Acute intermittent porphyria (AIP) is a disease affecting the heme biosynthesis pathway caused by mutations of the hydroxymethylbilane synthase (HMBS) gene. AIP is thought to display autosomal dominant inheritance with incomplete penetrance. We evaluated the prevalence, penetrance and heritability of AIP, in families with the disease from the French reference center for porphyria (CFP) (602 overt patients; 1968 relatives) and the general population, using Exome Variant Server (EVS; 12 990 alleles) data. The pathogenicity of the 42 missense variants identified was assessed in silico, and in vitro, by measuring residual HMBS activity of the recombinant protein. The minimal estimated prevalence of AIP in the general population was 1/1299. Thus, 50 000 subjects would be expected to carry the AIP genetic trait in France. Penetrance was estimated at 22.9% in families with AIP, but at only 0.5-1% in the general population. Intrafamily correlation studies showed correlations to be strong overall and modulated by kinship and the area in which the person was living, demonstrating strong influences of genetic and environmental modifiers on inheritance. Null alleles were associated with a more severe phenotype and a higher penetrance than for other mutant alleles. In conclusion, the striking difference in the penetrance of HMBS mutations between the general population and the French AIP families suggests that AIP inheritance does not follow the classical autosomal dominant model, instead of being modulated by strong environmental and genetic factors independent from HMBS. An oligogenic inheritance model with environmental modifiers might better explain AIP penetrance and heritability.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29360981     DOI: 10.1093/hmg/ddy030

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  20 in total

1.  Disease pharmacokinetic-pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA-based therapies.

Authors:  Zinnia P Parra-Guillen; Antonio Fontanellas; Lei Jiang; Daniel Jericó; Paolo Martini; Diego Vera-Yunca; Marjie Hard; Lin T Guey; Iñaki F Troconiz
Journal:  Br J Pharmacol       Date:  2020-04-14       Impact factor: 8.739

2.  Characterization of the hepatic transcriptome following phenobarbital induction in mice with AIP.

Authors:  Brenden Chen; Minghui Wang; Lin Gan; Bin Zhang; Robert J Desnick; Makiko Yasuda
Journal:  Mol Genet Metab       Date:  2019-01-06       Impact factor: 4.797

Review 3.  [Porphyrias-what is verified?]

Authors:  U Stölzel; I Kubisch; T Stauch
Journal:  Internist (Berl)       Date:  2018-12       Impact factor: 0.743

Review 4.  The acute hepatic porphyrias.

Authors:  Bruce Wang
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

5.  Acute intermittent porphyria: prevalence of pathogenic HMBS variants in China, and epidemiological survey in Hebei Province, China.

Authors:  Liyan Ma; Yu Tian; Xuan Qi; Pei Li; Jie Li; Qing Teng; Yuelin Ma; Songyun Zhang
Journal:  Ann Transl Med       Date:  2022-05

Review 6.  Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy.

Authors:  Chaudry Nasir Majeed; Christopher D Ma; Ted Xiao; Sean Rudnick; Herbert L Bonkovsky
Journal:  Drug Des Devel Ther       Date:  2022-06-16       Impact factor: 4.319

Review 7.  Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.

Authors:  Pedro Renato de Paula Brandão; Simoneide S Titze-de-Almeida; Ricardo Titze-de-Almeida
Journal:  Mol Diagn Ther       Date:  2020-02       Impact factor: 4.074

Review 8.  Recent advances on porphyria genetics: Inheritance, penetrance & molecular heterogeneity, including new modifying/causative genes.

Authors:  Makiko Yasuda; Brenden Chen; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2018-11-30       Impact factor: 4.797

Review 9.  Novel treatment options for acute hepatic porphyrias.

Authors:  Bruce Wang
Journal:  Curr Opin Gastroenterol       Date:  2021-05-01       Impact factor: 2.741

10.  Pathogenic and rare deleterious variants in multiple genes suggest oligogenic inheritance in recurrent exertional rhabdomyolysis.

Authors:  Nyamkhishig Sambuughin; Ognoon Mungunsukh; Mingqiang Ren; John F Capacchione; Iren Horkayne-Szakaly; Kevin Chuang; Sheila M Muldoon; Jonathan K Smith; Francis G O'Connor; Patricia A Deuster
Journal:  Mol Genet Metab Rep       Date:  2018-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.